Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group

2013233 citationsJournal Article

Authors

Gertjan J.L. Kaspers

Martin Zimmermann

Dirk Reinhardt

Brenda Gibson

R. Y. J. Tamminga

Olga Aleinikova · Belarusian Research Center For Pediatric Oncology and Hematology

H. Armendariz · Instituto Argentino de Diagnóstico y Tratamiento

Michael Dworzak

Sy Ha · Queen Mary University of London

Henrik Hasle

Abstract

DNX added to FLAG improves early treatment response in pediatric relapsed AML. Overall long-term survival was similar, but CBF-AML showed an improved survival with FLAG/DNX. International collaboration proved feasible and resulted in the best outcome for pediatric relapsed AML reported thus far.

Topics & Keywords

Acute Myeloid Leukemia Research Neutropenia and Cancer Infections Hematological disorders and diagnostics

Publication Details

Published in: Journal of Clinical Oncology

Volume 31, Issue 5, pp. 599-607

DOI: 10.1200/jco.2012.43.7384

Field-Weighted Citation Impact: 12.65

Command Palette

Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group

Authors

Abstract

Topics & Keywords

Publication Details